ATAI Life Sciences

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

Florian Brand

CEO and Co-Founder

13 past transactions

Intelgenx Technologies

Acquisition in 2024
IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

Beckley Psytech

Secondary Market in 2024
Beckley Psytech Limited is a biotechnology company based in Oxford, United Kingdom, that develops psychedelic drugs aimed at treating psychiatric and neurological disorders. Founded in 2014, it focuses on harnessing the therapeutic potential of substances such as psilocybin to address significant mental health challenges, including depression and other debilitating neuropsychiatric conditions with considerable unmet needs. The company aims to integrate clinically validated psychedelic medicines into mainstream medical practices, offering patients innovative treatment options that differentiate from existing therapies. Through its drug pipeline, Beckley Psytech is committed to providing alternative solutions for those suffering from various mental health issues.

Beckley Psytech

Corporate Round in 2024
Beckley Psytech Limited is a biotechnology company based in Oxford, United Kingdom, that develops psychedelic drugs aimed at treating psychiatric and neurological disorders. Founded in 2014, it focuses on harnessing the therapeutic potential of substances such as psilocybin to address significant mental health challenges, including depression and other debilitating neuropsychiatric conditions with considerable unmet needs. The company aims to integrate clinically validated psychedelic medicines into mainstream medical practices, offering patients innovative treatment options that differentiate from existing therapies. Through its drug pipeline, Beckley Psytech is committed to providing alternative solutions for those suffering from various mental health issues.

Intelgenx Technologies

Post in 2023
IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

Intelgenx Technologies

Post in 2023
IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

Intelgenx Technologies

Post in 2022
IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

Psyber

Acquisition in 2021
Psyber is a company focused on developing interventions for mental health disorders through brain-computer interface (BCI)-enabled digital therapeutics. By integrating BCI technology with psychedelics, Psyber creates therapeutic devices that monitor electrical activity in the brain, allowing for real-time interpretation of emotional, behavioral, and mental states. This innovative approach empowers patients who are prescribed medication, enabling them to modify their feelings and behaviors. Ultimately, Psyber aims to enhance the quality of life for individuals facing mental health challenges through advanced digital health solutions.

Intelgenx Technologies

Post in 2021
IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

Intelgenx Technologies

Post in 2021
IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

Recognify Life Sciences

Acquisition in 2021
Recognify Life Sciences is a biotechnology company focused on developing innovative treatments for cognitive impairment related to schizophrenia. The company is engaged in creating pharmaceutical therapies that aim to modulate the excitatory and inhibitory balance in the brain, which is essential for enhancing learning and memory. By addressing cognitive impairment, Recognify Life Sciences seeks to provide healthcare providers with effective treatment options for not only schizophrenia but also Alzheimer's and other neurodegenerative and neurocognitive diseases.

COMPASS Pathways

Series B in 2020
COMPASS Pathways is a mental health care company based in Cheshire, United Kingdom, with operations in the United States. The company is focused on developing innovative therapies for treatment-resistant depression (TRD) using its proprietary psilocybin formulation, COMP360. Currently undergoing Phase IIb clinical trials, COMP360 aims to provide a new treatment option for patients who have not responded to traditional depression therapies. COMPASS Pathways emphasizes the combination of psilocybin-assisted therapy with psychological support to enhance treatment efficacy. The company is committed to addressing the significant unmet needs in mental health care by advancing evidence-based solutions for those suffering from mental health challenges.

Innoplexus

Series C in 2019
Innoplexus AG specializes in developing artificial intelligence and blockchain-based products to assist enterprises in extracting insights from both structured and unstructured data. The company's offerings include Ontosight, which provides real-time information relevant to the pharmaceutical industry, and Ontosight Xplore, a pre-clinical drug discovery ecosystem that facilitates the exploration of connections between drugs, targets, pathways, and diseases. Additionally, Innoplexus offers a Clinical Trial Prediction Engine that utilizes AI to forecast clinical trial outcomes. The company also caters to the financial sector with its AI solutions, such as RegI, an AI-driven regulatory tool for managing compliance risks. Their Data as a Service (DaaS) and Continuous Analytics as a Service (CaaS) solutions help organizations in the banking and financial services sectors mitigate risks and enhance decision-making. Founded in 2011, Innoplexus is headquartered in Eschborn, Germany, with offices in India and the United States, and serves clients across pharmaceuticals, biotechnology, financial services, and academia.

Perception Neuroscience

Acquisition in 2019
Perception Neuroscience is a biopharmaceutical company dedicated to creating innovative therapies for neuropsychiatric disorders. The company is primarily focused on developing arketamine, an NMDA antagonist that aims to offer effective treatment solutions for serious psychiatric conditions. Arketamine is designed to provide rapid-acting antidepressant effects and has the potential to reduce suicidal ideation, addressing a critical need in mental health care. Through its research and development efforts, Perception Neuroscience seeks to improve outcomes for patients suffering from challenging psychiatric illnesses.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.